Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms.

Sorensen EW, Gerber SA, Frelinger JG, Lord EM.

J Immunol. 2010 Feb 15;184(4):1858-66. doi: 10.4049/jimmunol.0903210. Epub 2010 Jan 8.

2.

Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity.

Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM.

J Immunol. 2008 Mar 1;180(5):3132-9.

3.
4.

Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts.

Gerber SA, Moran JP, Frelinger JG, Frelinger JA, Fenton BM, Lord EM.

Br J Cancer. 2003 May 6;88(9):1453-61.

5.

Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-gamma pathway but not IL-12 or IL-18.

Wu TH, Pabin CN, Qin Z, Blankenstein T, Philip M, Dignam J, Schreiber K, Schreiber H.

J Immunol. 2004 Mar 1;172(5):3243-51.

6.

Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy.

Gerber SA, Sorensen EW, Sedlacek AL, Lim JY, Skrombolas D, Frelinger JG, Lord EM.

Immunology. 2013 Mar;138(3):280-92. doi: 10.1111/imm.12037.

7.

IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma.

Ma HL, Whitters MJ, Konz RF, Senices M, Young DA, Grusby MJ, Collins M, Dunussi-Joannopoulos K.

J Immunol. 2003 Jul 15;171(2):608-15.

8.

IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.

Osaki T, Péron JM, Cai Q, Okamura H, Robbins PD, Kurimoto M, Lotze MT, Tahara H.

J Immunol. 1998 Feb 15;160(4):1742-9.

9.

Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.

Asada H, Kishida T, Hirai H, Satoh E, Ohashi S, Takeuchi M, Kubo T, Kita M, Iwakura Y, Imanishi J, Mazda O.

Mol Ther. 2002 May;5(5 Pt 1):609-16.

10.
11.

Enhancing in vivo tumorigenicity of B16 melanoma by overexpressing interferon regulatory factor-2: resistance to endogenous IFN-gamma.

Yim JH, Wu SJ, Lowney JK, Vander Velde TL, Doherty GM.

J Interferon Cytokine Res. 1999 Jul;19(7):723-9.

PMID:
10454342
12.

Inhibition of IL-17A in tumor microenvironment augments cytotoxicity of tumor-infiltrating lymphocytes in tumor-bearing mice.

Hayata K, Iwahashi M, Ojima T, Katsuda M, Iida T, Nakamori M, Ueda K, Nakamura M, Miyazawa M, Tsuji T, Yamaue H.

PLoS One. 2013;8(1):e53131. doi: 10.1371/journal.pone.0053131. Epub 2013 Jan 25.

13.
14.
15.
16.

IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk.

Strasly M, Cavallo F, Geuna M, Mitola S, Colombo MP, Forni G, Bussolino F.

J Immunol. 2001 Mar 15;166(6):3890-9.

17.
18.

T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas.

Böhm W, Thoma S, Leithäuser F, Möller P, Schirmbeck R, Reimann J.

J Immunol. 1998 Jul 15;161(2):897-908.

19.

T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3.

Quatromoni JG, Morris LF, Donahue TR, Wang Y, McBride W, Chatila T, Economou JS.

J Hematol Oncol. 2011 Nov 23;4:48. doi: 10.1186/1756-8722-4-48.

20.

Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation.

García-Hernández ML, Hernández-Pando R, Gariglio P, Berumen J.

Immunology. 2002 Feb;105(2):231-43.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk